Biolegend, 135221, Brilliant Violet 421™ anti-mouse CD279 (PD-1) Antibody
50microg
Catalog Number: 135221
Send an RFQ.
Category
Loading…
| Verified Reactivity | Mouse |
|---|---|
| Antibody Type | Monoclonal |
| Host Species | Rat |
| Immunogen | PD-1 cDNA followed by PD-1-Ig fusion protein |
| Formulation | Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA). |
| Preparation | The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions. |
| Concentration | µg sizes: 0.2 mg/mLµL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.) |
| Storage & Handling | The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze. |
| Application | FC - Quality tested SB - Reported in the literature, not verified in house |
Unless otherwise stated, the minimum order amount is USD 1,000.
For orders below USD 1,000, an additional handling fee may apply, or we may arrange local delivery / local handover where available.
All quotations are subject to final confirmation, including product availability, lead time, batch information, shipping cost, and applicable export or handling requirements.
For quotation requests, please send an RFQ from website or contact:
Please send inquiries directly to us in the “To” field. Emails sent via BCC, mass mailing, or with unrelated recipients may be automatically filtered and will not be processed.
| Recommended Usage |
|---|
| Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.125 µg per million cells in 100 µl volume. For immunofluorescent staining using µl sizes, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application. Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd. Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents. |
| Excitation Laser | Violet Laser (405 nm) |
|---|
| Application Notes | Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue3, in vivo blocking of PD-1 binding to its ligands2,3, and spatial biology (IBEX)5,6. |
|---|
| Additional Product Notes | Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH). |
|---|
| Application References(PubMed link indicates BioLegend citation) | Good-Jacobson KL, et al. 2010. Nat. Immunol. 11:535. (FC) PubMed Lázár-Molnár E, et al. 2008. Proc. Natl. Acad. Sci. USA 105:2658. (Block) Liang SC, et al. 2003. Eur. J. Immunol. 33:2706. (FC, IHC, Block) Tobias J, et al. 2020. Front Immunol. 11:895 (FC, ELISA) PubMed Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed |
|---|
| Product Citations | Swan SL, et al. 2023. Front Immunol. 14:1085547. PubMed Tan X, et al. 2023. Adv Sci (Weinh). 10:e2206768. PubMed del Rio ML, et al. 2023. Front Immunol. 14:1113858. PubMed Palakurthi B, et al. 2023. Nat Commun. 14:2109. PubMed Tai W, et al. 2023. Nat Commun. 14:2962. PubMed Kuczynski EA, et al. 2022. EMBO Mol Med. 14:e15816. PubMed Shallberg LA, et al. 2022. PLoS Pathog. 18:e1010296. PubMed del Rio ML, et al. 2022. Front Immunol. 13:887348. PubMed VanDyke D, et al. 2022. Cell Rep. 41:111478. PubMed Tunali G, et al. 2023. J Clin Invest. :. PubMed Abu Hejleh AP, et al. 2023. Int J Tryptophan Res. 16:11786469231153111. PubMed Allen SD, et al. 2021. Biomaterials. 269:120635. PubMed Yeh CH, et al. 2022. Immunity. 55:272. PubMed Perry JA, et al. 2022. Nat Immunol. 23:743. PubMed Fitzgerald B, et al. 2021. Cell Rep Methods. 1:. PubMed Jiang W, et al. 2021. Oncol Lett. 22:625. PubMed Ogbechi J, et al. 2022. Front Immunol. 13:1001956. PubMed Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed Clemmensen HS, et al. 2021. MBio. 12:. PubMed Kim Y, et al. 2015. PLoS One. 10:120294. PubMed Nagai Y, et al. 2019. Front Immunol. 10:174. PubMed Wei SC, et al. 2019. Immunity. 50:1084. PubMed Silva M, et al. 2021. Sci Immunol. 6:eabf1152. PubMed Wang C, et al. 2021. Cell Rep. 37:110021. PubMed Clemmensen HS, et al. 2020. Front Immunol. 11:585359. PubMed Calvo-Barreiro L, et al. 2021. Neurotherapeutics. . PubMed Pein M, et al. 2020. Nat Commun. 11:1494. PubMed Liu H, et al. 2020. Cancer Cell. 37(3):324-339. PubMed Wong HS, et al. 2021. Cell. . PubMed Mehta AK, et al. 2021. Nat Cancer. 2:66. PubMed Synn CB, et al. 2022. Clin Transl Immunology. 11:e1364. PubMed Tavazoie MF, et al. 2018. Cell. 172:825. PubMed Martínez‐López M et al. 2019. Immunity. 50(2):446-461 . PubMed Li H, et al. 2021. Adv Sci (Weinh). 2001596:8. PubMed Yan J, et al. 2020. Cell Rep. 107820:31. PubMed Puigdelloses M, et al. 2021. J Immunother Cancer. 9:. PubMed RY H, et al. 2016. Oncoimmunology. 6:e1249561. PubMed Watson MJ, et al. 2021. Nature. 591:645. PubMed Zhang X, et al. 2021. Mol Cancer Res. 19:1076. PubMed Ryan NM, et al. 2022. Front Immunol. 13:932742. PubMed Kumagai S, et al. 2020. Immunity. 53(1):187-203.e8. PubMed Papa I, et al. 2017. Nature. 547:318. PubMed He C, et al. 2022. Nat Commun. 13:5459. PubMed Yuan M, et al. 2022. Oxid Med Cell Longev. 2022:5479491. PubMed Bent EH, et al. 2021. Nat Commun. 12:6218. PubMed Mulens-Arias V, et al. 2022. Pharmaceutics. 14:. PubMed Amobi-McCloud A, et al. 2021. Front Immunol. 12:678999. PubMed Nicolas-Boluda A, et al. 2021. eLife. 10:00. PubMed Wan X, Thomas J, Unanue E 2016. J Exp Med. 213: 967 - 978. PubMed Lau P, et al. 2022. Cell Mol Immunol. :. PubMed Kinsey G, et al. 2012. J Am Soc Nephrol. 23:1528. PubMed Szeto C, et al. 2022. Nat Commun. 13:4951. PubMed Gonzalez-Figueroa P, et al. 2021. Cell. 184(7):1775-1789.e19. PubMed Ye Y, et al. 2020. Genome Med. 0.557638889. PubMed Scala M, et al. 2016. J Virol. 90: 8563 - 8574. PubMed Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed Song X, et al. 2022. Transl Oncol. 15:101306. PubMed |
|---|
| RRID | AB_10900085 (BioLegend Cat. No. 135217) AB_2562568 (BioLegend Cat. No. 135221) AB_2561447 (BioLegend Cat. No. 135218) |
|---|
| Structure | A 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily. |
|---|
| Distribution | Induced on splenic T and B lymphocytes, thymocytes, and myeloid cells after stimulation. |
|---|
| Function | Involved in lymphocyte clonal selection and peripheral tolerance, prolonged survival of allografts. |
|---|
| Ligand/Receptor | B7-H1 (PD-L1) and B7-DC (PD-L2) |
|---|
| Cell Type | B cells, T cells |
|---|
| Biology Area | Cancer Biomarkers, Immunology, Inhibitory Molecules |
|---|
| Molecular Family | CD Molecules, Immune Checkpoint Receptors |
|---|
| Antigen References | 1. Nishimura H, et al. 2001. Science 291:319 2. Agata Y, et al. 1996. Int. Immunol. 8:765 3. Liang SC, et al. 2003. Eur. J. Immunol. 33:2706 4. Barber DL, et al. 2006. Nature 439:682 5. Keir ME, et al. 2005. J. Immunol. 175:7372 6. Koehn BH. et al. 2008. J Immunol. 181:5313 |
|---|
| Gene ID | 18566 |
|---|
| UniProt | View information about CD279 on UniProt.org |
|---|
| Clone | 29F.1A12 |
|---|
| Regulatory Status | RUO |
|---|
| Other Names | PD-1, Programmed Death-1, PDCD1 |
|---|
| Isotype | Rat IgG2a, κ |
|---|
